News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Sunstone portfolio company Galecto in successful IPO on Nasdaq Global Market in the US.
Sunstone today announced its portfolio company Galecto, a clinical stage biotech firm focusing on novel therapeutics for fibrosis and inflammatory-related lung diseases, successfully has launched an initial public offering (IPO) on Nasdaq Global Market in the U.S....
Sunstone welcomes Novo Holdings A/S as new LP in Sunstone Life Science Ventures Fund IV
Sunstone today announced that Novo Holdings A/S has joined as Limited Partner (LP) in Sunstone’s latest fund; Sunstone Life Science Ventures Fund IV (“Sunstone IV”) Sunstone has been collaborating with Novo Seeds and Novo Ventures, both a part of Novo Holdings, for...
Cantargias valberedning föreslår ny styrelseledamot
Valberedningen i Cantargia AB (publ), som består av Sten Verland (partner i Sunstone Life Science Ventures, ordförande), Jannis Kitsakis (Fjärde AP-fonden), Alexander Mata (Alecta Pensionförsäkring, ömsesidigt) och Magnus Persson (styrelseordförande i Cantargia),...
Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the...
Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has filed a registration statement on Form F-1 with the U.S....
F2G closes USD 60.8 Million financing to fund late stage development of novel mechanism antifungal agent
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that it has secured US $60.8 million in new financing from new and existing investors. The financing round is led by Cowen Healthcare...